Recent developments in the prosecution of the CRISPR-Cas9 patent in Europe highlight the differences between the intellectual property regimes of Europe and the United States.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Hsu, P.D. et al. Cell 157, 1262–1278 (2014).
Sheridan, C. Nat. Biotechnol. 32, 599–601 (2014).
Zhang, F. CRISPR-Cas systems and methods for altering expression of gene products. US patent 8697359 (2014).
Zhang, F. CRISPR-Cas systems and methods for altering expression of gene products. EP2764103 (2014).
Article 54(3) European Patent Convention.
https://register.epo.org/application?number=EP13824232&lng=en&tab=doclist
Letter of the applicant (the Broad Institute and MIT) dated 2 October, 2014. https://register.epo.org/application?number=EP13824232&lng=en&tab=doclist
Jinek, M. et al. Science 337, 816–821 (2012).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The author declares no competing financial interests.
Rights and permissions
About this article
Cite this article
Kupecz, A. Who owns CRISPR-Cas9 in Europe?. Nat Biotechnol 32, 1194–1196 (2014). https://doi.org/10.1038/nbt.3086
Published:
Issue Date:
DOI: https://doi.org/10.1038/nbt.3086
This article is cited by
-
Patent Law and Genome Engineering: A Short Guide to a Rapidly Changing Landscape
Molecular Therapy (2016)
-
Genome editing: intellectual property and product development in plant biotechnology
Plant Cell Reports (2016)